Disease Progression

//Disease Progression

An Easier, Cheaper and More Comfortable Way To Take Zytiga

Rather than taking – and paying – for the full Zytiga dose on an empty stomach, ask your doctor if you could get the same effect from taking just one fourth of your Zytiga dose while enjoying a low-fat or high-fat breakfast. A small phase two study of 36 prostate cancer patients who took 250 [...]

Men Who Fail Primary Radiation Can Have Good Results After Salvage Surgery

Men who have decided to have radiation as their first (primary) treatment for prostate cancer have a one-third chance of recurrence. Some of those men have salvage radical prostatectomy (SRP)  to fight the recurrence.  A study shows this might be a good idea. Antoni Vilaseca, MD, etal from Memorial Sloan-Kettering Cancer Center in New York, studied 251 men [...]

The 5 Important Questions We Need To Ask Men Who Are End Stage – Handling Grief

Advanced prostate cancer will eventually end, barring another cause of death, with the demise of the individual survivor. Knowing that you suffer from a terminal illness is hard, it is hard on the family and it is hard on the individual. Many of us don’t think about it, but it is also hard for many [...]

To Debulk Or Not To Debulk, That Is The Question

You have been diagnosed with advanced or metastatic prostate cancer. It is a shock, you have cancer and your cancer has already spread outside of the prostate gland. Your doctor might have already told you that at this stage it is no longer curable, and technically it can be called terminal! That is a lot [...]

Standardizing PSA Definition of Biochemical Recurrence after Radical Prostatectomy

There are multiple definitions of biochemical recurrence for prostate cancer treatment post surgery. This causes confusion both within the patient community and the medical community. It would be very helpful if we could standardize a simple measure, PSA as the biomarker for a biochemical recurrence. Standardization post surgery would give us a better way to [...]

Real Life Issues About Abiraterone Acetate (Zytiga) Prior to Chemotherapy – Unanticipated Real-World Clinical Experience Worth Noting

Researchers in Hong Kong wanted to confirm the efficacy of abiraterone acetate (Zytiga) used prior to chemotherapy that had been shown in the trial setting. In their analysis they came up short; raising some very significant concerns about Zytiga’s efficacy when used prior to chemotherapy. They reviewed the clinical records of men with metastatic castrate [...]

Why I Believe Xtandi Is Superior To Zytiga

I believe that Xtandi (enzalutamide) is a superior drug compared to Zytiga (abiraterone). Here's why. The phase III trials for both Xtandi and Zytiga were very similar to each other. In both trials investigators measured the percentage of men who progressed or died against placebo. In this very important measurement Xtandi blew Zytiga out of the [...]

A Small Analysis of Abiraterone Responses in African American Men with Metastatic Castration Resistant Prostate Cancer

Presented at ASCO GU by Stolten and colleagues was abstract 244 that described the responses African American men had to abiraterone (Zytiga) in a retrospective cohort study of men seen at a single institution.  Stolten included differences in the men including their age at diagnosis, prior enzalutamide (Xtandi) and/or docetaxel (chemotherapy) use, as well as [...]

Soon To Launch in Dublin – GAP4 Clinical Trial of Exercise for Men with Advanced Prostate Cancer

Can exercise improve the quality of life of men with advanced prostate cancer and also extend their survival? To help answer this question a major new global trial known as GAP4 has been launched in Dublin, Ireland. The trial has a goal of recruiting 866 men from seven countries, including Ireland. The trial will be [...]